Solid Tumor, ART0380C001 “ARTIOS”

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors.

Lung, Tempus Gemini TP-CA-002

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Lung, Tempus Aries TP-CA-007

A Second Line Biobank Registry Platform Study in Oncology Patients with KRAS mutated CRC, NSCLC & PDAC. Reference arm study to evaluate ctDNA kinetics and dynamics in response to standard of care therapy in patients with relapsed and metastatic KRAS-mutated NSCLC to enable novel biomarker discovery and drug development.

Lung, Ovation-23-001

The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations. 

Patient Newsletter 2024 October

Patient Newsletter 2024 September

Patient Newsletter 2024 August

HOA is the First Cancer Care Center in New York State to Offer Bispecific Antibody Therapy in an Outpatient Setting - Eliminating the Need for a Mandatory Hospital Stay

Hematology-Oncology Associates of CNY (HOA) has successfully treated a patient with bispecific antibody therapy for small-cell lung cancer as an outpatient. Reports show that while this therapy has been successfully administered in the outpatient setting in other parts of the United States, this is the first time it has been provided for someone outside of the hospital in New York State.

CNY cancer practice plans to ramp up cutting-edge therapy after successful outpatient treatment

Gail Mauro (center) receives her final step-up dose of bispecific antibody therapy at Hematology-Oncology Associates of CNY. She is pictured here with her husband, Joe (right) along with HOA Physician Assistant and Clinical Manager Denise Lougee. Joe serves as Gail’s at-home caregiver, which is a requirement of this new program.

Courtesy of HOA

 

By 

Lung Cancer Information

Pages